15-Deoxy-delta 12,14-prostaglandin J2 induces apoptosis in human malignant B cells: an effect associated with inhibition of NF-kappa B activity and down-regulation of antiapoptotic proteins.

Cyclopentenone prostaglandins are potent inhibitors of nuclear factor-kappa B (NF-kappa B), a transcription factor with a critical role in promoting inflammation and connected with multiple aspects of oncogenesis and cancer cell survival. In the present report, we investigated the role of NF-kappa B in the antineoplastic activity of the cyclopentenone prostaglandin 15-deoxy-Delta(12,14)-PGJ(2) (15d-PGJ(2)) in multiple myeloma (MM) and Burkitt lymphoma (BL) cells expressing constitutively active NF-kappa B. 15d-PGJ(2) was found to suppress constitutive NF-kappa B activity and potently induce apoptosis in both types of B-cell malignancies. 15d-PGJ(2)-induced apoptosis occurs through multiple caspase activation pathways involving caspase-8 and caspase-9, and is prevented by pretreatment with the pan-caspase inhibitor ZVAD (z-Val-Ala-Asp). NF-kappa B inhibition is accompanied by rapid down-regulation of NF-kappa B-dependent antiapoptotic gene products, including cellular inhibitor-of-apoptosis protein 1 (cIAP-1), cIAP-2, X-chromosome-linked inhibitor-of-apoptosis protein (XIAP), and FLICE-inhibitory protein (cFLIP). These effects were mimicked by the proteasome inhibitor MG-132, but not by the peroxisome proliferator-activated receptor-gamma (PPAR-gamma) agonist troglitazone, suggesting that 15d-PGJ(2)-induced apoptosis is independent of PPAR-gamma. Knockdown of the NF-kappa B p65-subunit by lentiviral-mediated shRNA interference also resulted in apoptosis induction in malignant B cells with constitutively active NF-kappa B. The results indicate that inhibition of NF-kappa B plays a major role in the proapoptotic activity of 15d-PGJ(2) in aggressive B-cell malignancies characterized by aberrant regulation of NF-kappa B.

[1]  I. Verma,et al.  CRE recombinase-inducible RNA interference mediated by lentiviral vectors. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[2]  K. Lauber,et al.  Cyclopentenone Prostaglandins Induce Lymphocyte Apoptosis by Activating the Mitochondrial Apoptosis Pathway Independent of External Death Receptor Signaling 1 , 2003, The Journal of Immunology.

[3]  P. Richardson,et al.  Novel therapeutic approaches for multiple myeloma , 2003, Immunological reviews.

[4]  Federica Briatore,et al.  Peroxisome Proliferator-Activated Receptor Ligands Affect Growth-Related Gene Expression in Human Leukemic Cells , 2003, Journal of Pharmacology and Experimental Therapeutics.

[5]  C. Amici,et al.  NEW EMBO MEMBER’S REVIEW: NF-κB and virus infection: who controls whom , 2003 .

[6]  S. Hilsenbeck,et al.  Arsenic trioxide-induced apoptosis in myeloma cells: p53-dependent G1 or G2/M cell cycle arrest, activation of caspase-8 or caspase-9, and synergy with APO2/TRAIL. , 2003, Blood.

[7]  Jen-kun Lin,et al.  Involvement of c‐jun N‐terminal kinase activation in 15‐deoxy‐δ12,14‐prostaglandin J2–and prostaglandin A1–induced apoptosis in AGS gastric epithelial cells , 2003, Molecular carcinogenesis.

[8]  K. Anderson,et al.  Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. , 2003, Blood.

[9]  Sujay K. Singh,et al.  Curcumin (diferuloylmethane) down-regulates the constitutive activation of nuclear factor–κB and IκBα kinase in human multiple myeloma cells, leading to suppression of proliferation and induction of apoptosis , 2003 .

[10]  A. Hamburger,et al.  15-PGJ2, but not thiazolidinediones, inhibits cell growth, induces apoptosis, and causes downregulation of Stat3 in human oral SCCa cells , 2002, British Journal of Cancer.

[11]  Kevin P. High,et al.  15-Deoxy-Δ12,14-prostaglandin J2-induced apoptosis does not require PPARγ in breast cancer cells Published, JLR Papers in Press, August 16, 2002. DOI 10.1194/jlr.M200224-JLR200 , 2002, Journal of Lipid Research.

[12]  T. Libermann,et al.  Molecular sequelae of proteasome inhibition in human multiple myeloma cells , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[13]  I. Verma,et al.  NF-κB regulation in the immune system , 2002, Nature Reviews Immunology.

[14]  W. Brugger,et al.  Cyclopentenone prostaglandins induce caspase activation and apoptosis in dendritic cells by a PPAR-gamma-independent mechanism: regulation by inflammatory and T cell-derived stimuli. , 2002, Experimental hematology.

[15]  L. Füzesi,et al.  Agonists of peroxisome proliferator-activated receptor gamma inhibit cell growth in malignant melanoma. , 2002, The Journal of investigative dermatology.

[16]  C. Sawyers,et al.  The phosphatidylinositol 3-Kinase–AKT pathway in human cancer , 2002, Nature Reviews Cancer.

[17]  C. Haslett,et al.  Prostaglandin D2 and Its Metabolites Induce Caspase-Dependent Granulocyte Apoptosis That Is Mediated Via Inhibition of IκBα Degradation Using a Peroxisome Proliferator-Activated Receptor-γ-Independent Mechanism1 , 2002, The Journal of Immunology.

[18]  T. Zander,et al.  Induction of apoptosis in human and rat glioma by agonists of the nuclear receptor PPARγ , 2002 .

[19]  N. Munshi,et al.  Biologic sequelae of nuclear factor-kappaB blockade in multiple myeloma: therapeutic applications. , 2002, Blood.

[20]  N. Munshi,et al.  NF-κB as a Therapeutic Target in Multiple Myeloma* , 2002, The Journal of Biological Chemistry.

[21]  M. Karin,et al.  AP-1 as a regulator of cell life and death , 2002, Nature Cell Biology.

[22]  J. Morrow,et al.  Products of the isoprostane pathway: unique bioactive compounds and markers of lipid peroxidation , 2002, Cellular and Molecular Life Sciences CMLS.

[23]  A. Terano,et al.  Characteristics of the peroxisome proliferator activated receptor γ (PPARγ) ligand induced apoptosis in colon cancer cells , 2002, Gut.

[24]  R. Phipps,et al.  Human B Lymphocytes and B Lymphomas Express PPAR-γ and Are Killed by PPAR-γ Agonists , 2002 .

[25]  Michael Karin,et al.  NF-κB in cancer: from innocent bystander to major culprit , 2002, Nature Reviews Cancer.

[26]  Michael Karin,et al.  NF-κB at the crossroads of life and death , 2002, Nature Immunology.

[27]  Ulrich Siebenlist,et al.  Constitutive Nuclear Factor κB Activity Is Required for Survival of Activated B Cell–like Diffuse Large B Cell Lymphoma Cells , 2001, The Journal of experimental medicine.

[28]  S. Alkan,et al.  Analysis of expression of nuclear factor κB (NF‐κB) in multiple myeloma: downregulation of NF‐κB induces apoptosis , 2001 .

[29]  C. Amici,et al.  Activation of I kappa b kinase by herpes simplex virus type 1. A novel target for anti-herpetic therapy. , 2001, The Journal of biological chemistry.

[30]  B. Rovin,et al.  Cyclopentenone prostaglandins inhibit cytokine-induced nf-kappab activation and chemokine production by human mesangial cells. , 2001, Journal of the American Society of Nephrology : JASN.

[31]  S. Boyault,et al.  15‐Deoxy‐Δ12,14‐PGJ2, but not troglitazone, modulates IL‐1β effects in human chondrocytes by inhibiting NF‐κB and AP‐1 activation pathways , 2001 .

[32]  C. Hirschberg.  Golgi nucleotide sugar transport and leukocyte adhesion deficiency II , 2001 .

[33]  H. Kantarjian,et al.  Down-regulation of interleukin-3/granulocyte-macrophage colony-stimulating factor receptor beta-chain in BCR-ABL(+) human leukemic cells: association with loss of cytokine-mediated Stat-5 activation and protection from apoptosis after BCR-ABL inhibition. , 2001, Blood.

[34]  C. Glass,et al.  Cyclopentenone prostaglandins: New insights on biological activities and cellular targets , 2001, Medicinal research reviews.

[35]  P. Elliott,et al.  The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. , 2001, Cancer research.

[36]  Terry J. Smith,et al.  Peroxisome Proliferator Activator Receptor-γ Agonists and 15-Deoxy-Δ12,1412,14-PGJ2 Induce Apoptosis in Normal and Malignant B-Lineage Cells1 , 2000, The Journal of Immunology.

[37]  L. Boxer,et al.  NF-κB Activity Is Required for the Deregulation of c-myc Expression by the Immunoglobulin Heavy Chain Enhancer* , 2000, The Journal of Biological Chemistry.

[38]  C. Glass,et al.  15-deoxy-delta 12,14-prostaglandin J2 inhibits multiple steps in the NF-kappa B signaling pathway. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[39]  M. Kondo,et al.  Inhibition of human lung cancer cell growth by the peroxisome proliferator-activated receptor-gamma agonists through induction of apoptosis. , 2000, Biochemical and biophysical research communications.

[40]  G. Natoli,et al.  Anti-inflammatory cyclopentenone prostaglandins are direct inhibitors of IκB kinase , 2000, Nature.

[41]  B. Rayet,et al.  Aberrant rel/nfkb genes and activity in human cancer , 1999, Oncogene.

[42]  M. Willingham,et al.  Influence of J series prostaglandins on apoptosis and tumorigenesis of breast cancer cells. , 1999, Carcinogenesis.

[43]  Chris Albanese,et al.  NF-κB Controls Cell Growth and Differentiation through Transcriptional Regulation of Cyclin D1 , 1999, Molecular and Cellular Biology.

[44]  D. Gilroy,et al.  Inducible cyclooxygenase may have anti-inflammatory properties , 1999, Nature Medicine.

[45]  B. Barlogie,et al.  Role of NF-kappaB in the rescue of multiple myeloma cells from glucocorticoid-induced apoptosis by bcl-2. , 1999, Blood.

[46]  J. Morrow,et al.  Formation of Reactive Cyclopentenone Compounds in Vivo as Products of the Isoprostane Pathway* , 1999, The Journal of Biological Chemistry.

[47]  T. Sakai,et al.  p53-Independent Activation of the gadd45 Promoter by Δ12-Prostaglandin J2 , 1998 .

[48]  M. Grever,et al.  Tumor growth inhibition induced in a murine model of human Burkitt's lymphoma by a proteasome inhibitor. , 1998, Cancer research.

[49]  B. Dörken,et al.  Constitutive nuclear factor-kappaB-RelA activation is required for proliferation and survival of Hodgkin's disease tumor cells. , 1997, The Journal of clinical investigation.

[50]  David M. Rothwarf,et al.  A cytokine-responsive IκB kinase that activates the transcription factor NF-κB , 1997, Nature.

[51]  M. Santoro.  Antiviral activity of cyclopentenone prostanoids. , 1997, Trends in microbiology.

[52]  K. Bhatia,et al.  Role of the p53 tumor suppressor gene in the tumorigenicity of Burkitt's lymphoma cells. , 1997, Cancer research.

[53]  A. Rossi,et al.  Inhibition of nuclear factor kappa B by prostaglandin A1: an effect associated with heat shock transcription factor activation. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[54]  A. Rossi,et al.  2-Cyclopenten-1-one, a New Inducer of Heat Shock Protein 70 with Antiviral Activity* , 1996, The Journal of Biological Chemistry.

[55]  J. Lehmann,et al.  A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor γ and promotes adipocyte differentiation , 1995, Cell.

[56]  Jeong-Hwa Lee,et al.  Induction of p53 and apoptosis by δ 12‐PGJ2 in human hepatocarcinoma SK‐HEP‐1 cells , 1995 .

[57]  David Baltimore,et al.  Embryonic lethality and liver degeneration in mice lacking the RelA component of NF-κB , 1995, Nature.

[58]  F. A. La Rosa,et al.  Differential regulation of the c-myc oncogene promoter by the NF-kappa B rel family of transcription factors , 1994, Molecular and cellular biology.

[59]  J. Vane,et al.  Therapeutic Applications of Prostaglandins , 1993 .

[60]  F. A. La Rosa,et al.  A novel NF-kappa B element within exon 1 of the murine c-myc gene. , 1992, Oncogene.

[61]  M. Siekevitz,et al.  Transactivation of the c-myc promoter by human T cell leukemia virus type 1 tax is mediated by NF kappa B. , 1992, The Journal of biological chemistry.

[62]  U Zabel,et al.  DNA binding of purified transcription factor NF-kappa B. Affinity, specificity, Zn2+ dependence, and differential half-site recognition. , 1991, The Journal of biological chemistry.

[63]  R. Morimoto,et al.  Coordinate changes in heat shock element-binding activity and HSP70 gene transcription rates in human cells. , 1988, Molecular and cellular biology.

[64]  C. Amici,et al.  Modulation of the growth of a human erythroleukemic cell line (K562) by prostaglandins: antiproliferative action of prostaglandin A. , 1986, Cancer research.

[65]  B. Jaffe,et al.  Prostaglandin A1 induces differentiation in Friend erythroleukemia cells. , 1979, Prostaglandins.

[66]  L. Pham,et al.  A CD40 Signalosome anchored in lipid rafts leads to constitutive activation of NF-kappaB and autonomous cell growth in B cell lymphomas. , 2002, Immunity.

[67]  A. Baldwin.  Series Introduction: The transcription factor NF-κB and human disease , 2001 .

[68]  D. Straus.  15-deoxy Δ^ -PGJ2 inhibits multiple steps in the NF-kappaB signaling pathway , 2000 .

[69]  D. Tindall,et al.  Nonapoptotic cell death associated with S-phase arrest of prostate cancer cells via the peroxisome proliferator-activated receptor γ ligand, 15-deoxy-Δ12,14-prostaglandin J2 , 2000 .

[70]  M. Karin,et al.  Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity. , 2000, Annual review of immunology.

[71]  M J May,et al.  NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses. , 1998, Annual review of immunology.

[72]  M. Shield.  Novel applications of misoprostol. , 1995, Pharmacology & therapeutics.